142_CD GlaxoSmithKline_NNP Financial_NNP record_NN Quarterly_JJ trend_NN An_DT unaudited_JJ analysis_NN is_VBZ provided_VBN by_IN quarter_NN of_IN the_DT Group_NNP results_NNS in_IN sterling_NN for_IN the_DT financial_JJ year_NN 2002_CD ._.
The_DT analysis_NN comprises_VBZ statutory_JJ results_NNS ,_, business_NN performance_NN results_NNS and_CC pharmaceutical_JJ sales_NNS by_IN therapeutic_JJ area_NN ._.
Merger_NN ,_, restructuring_NN and_CC disposal_NN of_IN subsidiaries_NNS Manufacturing_NNP and_CC other_JJ restructuring_NN 362 162 171 443_CD 90_CD Merger_NN costs_NNS and_CC product_NN divestments_NNS 599_CD 1,069_CD 895_CD Other_JJ items_NNS 50_CD 421_CD 22_CD 29_CD 721_CD Loss_NN profit_NN before_IN taxation_NN 1,011_CD 1,652_CD 702 472 811_CD Loss_NN profit_NN attributable_JJ to_TO shareholders_NNS 712_CD 1,330_CD 452 347 512_CD Business_NN performance_NN results_NNS -_: retained_VBN businesses_NNS Sales_NNS 21,212_CD 20,489_CD 18,079_CD 16,164_CD 14,938_CD R&D_NNP expenditure_NN 2,732_CD 2,555_CD 2,510_CD 2,285_CD 2,072_CD per_IN cent_NN of_IN sales_NNS 13_CD 12_CD 14_CD 14_CD 14_CD Trading_NN profit_NN 6,694_CD 6,053_CD 5,026_CD 4,378_CD 4,191_CD per_IN cent_NN of_IN sales_NNS 32_CD 30_CD 28_CD 27_CD 28_CD Net_JJ interest_NN payable_JJ 141 88 182 162_CD 192_CD profit_NN before_IN taxation_NN 6,517_CD 6,169_CD 5,327_CD 4,683_CD 4,299_CD Adjusted_VBN earnings_NNS profit_NN attributable_JJ to_TO shareholders_NNS 4,627_CD 4,383_CD 3,654_CD 3,406_CD 2,892_CD Business_NN performance_NN ,_, which_WDT is_VBZ the_DT primary_JJ performance_NN measure_NN used_VBN by_IN management_NN ,_, is_VBZ presented_VBN after_IN excluding_VBG merger_NN items_NNS ,_, integration_NN and_CC restructuring_NN costs_NNS and_CC the_DT disposal_NN of_IN businesses_NNS ._.
Management_NNP believes_VBZ that_IN exclusion_NN of_IN these_DT non-recurring_JJ items_NNS provides_VBZ a_DT better_JJR comparison_NN of_IN business_NN performance_NN for_IN the_DT periods_NNS presented_VBN ._.
Accordingly_RB ,_, this_DT information_NN is_VBZ provided_VBN as_IN a_DT supplement_NN to_TO that_DT included_VBN in_IN the_DT Consolidated_NNP statement_NN of_IN profit_NN and_CC loss_NN on_IN pages_NNS 76_CD and_CC 77_CD prepared_JJ in_IN accordance_NN with_IN UK_NNP GAAP_NNP ._.
Statutory_JJ results_NNS include_VBP these_DT non-recurring_JJ items_NNS ._.
Share_NN statistics_NNS Earnings_NNS per_IN Share_NN p_NN 66.2_CD 50.3_CD 67.7_CD 50.3_CD 39.9_CD Dividends_NNPS per_IN GlaxoSmithKline_NNP share_NN p_NN :_: GlaxoSmithKline_NNP shareholder_NN 40.0_CD 39.0_CD Glaxo_NNP Wellcome_NNP shareholder_NN 38.0_CD 37.0_CD 36.0_CD SmithKline_NNP Beecham_NNP shareholder_NN 29.66_CD 26.69_CD 24.02_CD Dividends_NNS per_IN GlaxoSmithKline_NNP ADS_NNPS $_$ :_: GlaxoSmithKline_JJ shareholder_NN 1.24_CD 1.11_CD Glaxo_NNP Wellcome_NNP shareholder_NN 1.10_CD 1.14_CD 1.19_CD SmithKline_NNP Beecham_NNP shareholder_NN 0.87_CD 0.86_CD 0.81_CD Dividends_NNS are_VBP expressed_VBN in_IN terms_NNS of_IN a_DT GlaxoSmithKline_NNP share_NN ADS_NNPS ._.
On_IN the_DT merger_NN between_IN Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP on_IN 27th_JJ December_NNP 2000_CD ,_, shareholders_NNS and_CC ADR_NNP holders_NNS received_VBD shares_NNS in_IN GlaxoSmithKline_NNP in_IN the_DT following_JJ ratios_NNS :_: for_IN 1_CD Glaxo_NNP Wellcome_NNP share_NN 1_CD GlaxoSmithKline_NNP share_NN for_IN 1_CD SmithKline_NNP Beecham_NNP share_NN 0.4552_CD GlaxoSmithKline_NNP shares_NNS for_IN 1_CD Glaxo_NNP Wellcome_NNP ADS_NNPS 1_CD GlaxoSmithKline_NNP ADS_NNPS for_IN 1_CD SmithKline_NNP Beecham_NNP ADS_NNPS 1.138_CD GlaxoSmithKline_NNP ADSs_NNPS 1_CD GlaxoSmithKline_NNP ADS_NNPS represents_VBZ 2_CD GlaxoSmithKline_NNP shares_NNS ._.
It_PRP excludes_VBZ those_DT employees_NNS who_WP are_VBP employed_VBN and_CC managed_VBN by_IN GlaxoSmithKline_NNP on_IN a_DT contract_NN basis_NN ._.
